AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10204832 — intervention group
Group type: COMPARATOR
Intervention: Coarse or a mixture of ultra-fine and coarse wheat bran (2-week ad libitum diet)
Number of subjects: 48
Study 7772514 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vincristine (4 mg/m2 over 4 d) combined with fractionated total body irradiation (F-TBI) (200 cGy x 2 over 3 d) and cyclophosphamide (60 mg/kg for 2 d) in AlloBMT
Number of subjects: 75
Study 7772514 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vincristine (4 mg/m2 over 4 d) combined with fractionated total body irradiation (F-TBI) (200 cGy x 2 over 3 d) and cyclophosphamide (60 mg/kg for 2 d) in ABMT
Number of subjects: 75
Study 7772514 — intervention group
Group type: COMPARATOR
Intervention: AlloBMT
Number of subjects: 75
Study 7772514 — intervention group
Group type: COMPARATOR
Intervention: ABMT
Number of subjects: 75
Study 2189452 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms/kg
Number of subjects: 60
Study 2189452 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms/kg
Number of subjects: 60
Study 2189452 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2 mg/kg
Number of subjects: 60
Study 2189452 — intervention group
Group type: COMPARATOR
Intervention: Saline 10 ml
Number of subjects: 60
Study 457017 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Allopurinol
Number of subjects: 12
Study 457017 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Benzbromarone
Number of subjects: 12
Study 457017 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Allopurinol and Benzbromarone
Number of subjects: 12
Study 30482651 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical U-shape splitting technique
Number of subjects: 36
Study 30482651 — intervention group
Group type: COMPARATOR
Intervention: Guided bone regeneration (GBR)
Number of subjects: 36
Study 29405611 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 69
Study 29405611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 26840133 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (3.0 g per day)
Number of subjects: 400
Study 26840133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 24354519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue kallikrein treatment (intravenous infusion of tissue kallikrein 0.15 PNAU/d for 7 days, followed by oral pancreatic kallikrein enteric-coated tablet 240 U, 3 times a day)
Number of subjects: 90
Study 24354519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tissue kallikrein treatment)
Number of subjects: 90
Study 22958295 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 quality aspects of hospitals
Number of subjects: 414
Study 22958295 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 quality aspects of hospitals
Number of subjects: 414
Study 22958295 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 quality aspects of hospitals
Number of subjects: 414
Study 22958295 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 quality aspects of hospitals
Number of subjects: 414
Study 22958295 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer characteristics (especially age) and skills (especially literacy)
Number of subjects: 414
Study 22958295 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice behaviour
Number of subjects: 414
Study 22958295 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of information
Number of subjects: 414
Study 20980943 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg intravenous N-acetylcysteine (NAC)
Number of subjects: 60
Study 20980943 — intervention group
Group type: COMPARATOR
Intervention: No N-acetylcysteine (Control)
Number of subjects: 60
Study 17320198 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 (10 pmol kg(‐1) min(‐1))
Number of subjects: 12
Study 17320198 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38
Number of subjects: 12
Study 17320198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 12
Study 16265685 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 45
Study 16265685 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg/day)
Number of subjects: 45
Study 16265685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11901039 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin for 5 weeks
Number of subjects: 40
Study 11901039 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 40
Study 11901039 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40
Study 11901039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10978973 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon mitral valvuloplasty (BMV)
Number of subjects: 51
Study 8994013 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP UD (MUD) splint
Number of subjects: 26
Study 1619103 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cranial radiation therapy
Number of subjects: 49
Study 1619103 — intervention group
Group type: COMPARATOR
Intervention: High-dose chemotherapy
Number of subjects: 49
Study 1619103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 49
Study 6496209 — intervention group
Group type: EXPERIMENTAL
Intervention: Group monetary contracts
Number of subjects: 0
Study 6496209 — intervention group
Group type: COMPARATOR
Intervention: Individual monetary contracts
Number of subjects: 0
Study 31617857 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support supplemented with Cognitive Remediation and Work-Focused Social Skills Training
Number of subjects: 0
Study 29321686 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring intervention group
Number of subjects: 50
Study 29321686 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasoning intervention group
Number of subjects: 50
Study 27018995 — intervention group
Group type: EXPERIMENTAL
Intervention: LTOT + TA
Number of subjects: 0
Study 27018995 — intervention group
Group type: EXPERIMENTAL
Intervention: LTOT + NIV + TA
Number of subjects: 0
Study 27018995 — intervention group
Group type: COMPARATOR
Intervention: LTOT
Number of subjects: 0
Study 27018995 — intervention group
Group type: COMPARATOR
Intervention: LTOT + NIV
Number of subjects: 0
Study 25029210 — intervention group
Group type: EXPERIMENTAL
Intervention: Fr + G (13C‐labelled fructose, unlabeled glucose, lipids and protein)
Number of subjects: 8
Study 25029210 — intervention group
Group type: EXPERIMENTAL
Intervention: Fr (13C‐labelled fructose, lipids and protein)
Number of subjects: 8
Study 25029210 — intervention group
Group type: COMPARATOR
Intervention: Fr + G
Number of subjects: 8
Study 23157043 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dinoprostone vaginal insert single dose
Number of subjects: 100
Study 23157043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 100
Study 20517830 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomifene + Metformin (Metformin 850 mg twice a day for 8 weeks, Clomifene 100 mg per day for 5 days)
Number of subjects: 63
Study 20517830 — intervention group
Group type: COMPARATOR
Intervention: Clomifene only (100 mg per day for 5 days)
Number of subjects: 63
Study 18480685 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 18480685 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 18480685 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 16182989 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (physicians using Wood lamp)
Number of subjects: 150
Study 16182989 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (physicians using Wood lamp)
Number of subjects: 150
Study 16182989 — intervention group
Group type: COMPARATOR
Intervention: Interrater agreement
Number of subjects: 150
Study 16182989 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarater agreement for Group 1
Number of subjects: 150
Study 16182989 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarater agreement for Group 2
Number of subjects: 150
Study 16182989 — intervention group
Group type: COMPARATOR
Intervention: Prevalence of urine fluorescence
Number of subjects: 150
Study 12527974 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO solution
Number of subjects: 14
Study 12527974 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% CHO solution
Number of subjects: 14
Study 12527974 — intervention group
Group type: COMPARATOR
Intervention: 0% CHO solution
Number of subjects: 14
Study 10658884 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-session stress management group
Number of subjects: 178
Study 10658884 — intervention group
Group type: COMPARATOR
Intervention: usual-care control condition
Number of subjects: 178
Study 8892196 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 128
Study 8892196 — intervention group
Group type: COMPARATOR
Intervention: Chest radiographs
Number of subjects: 128
Study 1508061 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (50 or 100 micrograms/24 h) combined with oral progestogen (5 mg medroxyprogesterone acetate for 14 days each cycle)
Number of subjects: 59
Study 30768383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 269
Study 30768383 — intervention group
Group type: COMPARATOR
Intervention: Extended treatment with continued CBT or pharmacotherapy with sertraline
Number of subjects: 269
Study 31492103 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion (20 IU insulin with 10 mEq KCL in 50 ml glucose 40%)
Number of subjects: 0
Study 31492103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 0
Study 31492103 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) pretreatment after cardiopulmonary bypass
Number of subjects: 0
Study 31492103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after cardiopulmonary bypass)
Number of subjects: 0
Study 28196160 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + SMV (1.2 mg Simvastatin gel)
Number of subjects: 24
Study 28196160 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo gel
Number of subjects: 24
Study 26270952 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalisation of SF by 3-weekly erythrocytapheresis
Number of subjects: 0
Study 26270952 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment with 3-weekly plasmapheresis (no normalisation of SF)
Number of subjects: 0
Study 23568224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg for 4 days, coadministration with macitentan on day 5, continued for 19 additional days
Number of subjects: 10
Study 23568224 — intervention group
Group type: COMPARATOR
Intervention: Macitentan 10 mg single oral dose
Number of subjects: 10
Study 20686810 — intervention group
Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 148
Study 20686810 — intervention group
Group type: COMPARATOR
Intervention: rizatriptan 10 mg
Number of subjects: 148
Study 19583868 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted postoperative IV fluid regime (1.5 L/24 h)
Number of subjects: 62
Study 19583868 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative IV fluid regime (2.5 L/24 h)
Number of subjects: 62
Study 19583868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 17972615 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-circuit isoflurane-based anesthesia (CIA)
Number of subjects: 50
Study 17972615 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl/propofol-based anesthesia (FPA)
Number of subjects: 50
Study 15218314 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tegafur (TG) 500 mg/m²/day p.o. for 6 months plus four courses of mitomycin C (MMC) 10-20 mg/m² i.v. every 6 weeks
Number of subjects: 94
Study 15218314 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC) alone
Number of subjects: 94
Study 15218314 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tegafur (TG) plus MMC
Number of subjects: 94
Study 15218314 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tegafur (TG) plus MMC in low-TS patients
Number of subjects: 94
Study 15218314 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC) alone in low-TS patients
Number of subjects: 94
Study 11674935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotic therapy (IVAT)
Number of subjects: 125
Study 9758242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg daily
Number of subjects: 4
Study 9758242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg daily
Number of subjects: 4
Study 9758242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 4
Study 9758242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 7846741 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (1 mg/kg/day) administered either intravenously or orally at a dose of 0.5 mg/kg twice a day (maximum: 40 mg/day)
Number of subjects: 14
Study 7846741 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (1 mg/kg/day) administered either intravenously or orally
Number of subjects: 14
Study 7846741 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (0.5 mg/kg twice a day for 8 weeks)
Number of subjects: 14
Study 3072347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice a day
Number of subjects: 16
Study 3072347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg twice a day
Number of subjects: 16
Study 3072347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3072347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (any dose) in white patients
Number of subjects: 16
Study 3072347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (any dose) in black patients
Number of subjects: 16
Study 31775582 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (66 sessions)
Number of subjects: 76
Study 31775582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychotherapy)
Number of subjects: 76
Study 30941485 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective functional recovery tests (Timed Up and Go test, knee extensor and flexor strength)
Number of subjects: 173
Study 30941485 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength assessment
Number of subjects: 173
Study 30941485 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective physical functioning (SF-36 questionnaire)
Number of subjects: 173
Study 28619305 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening during waiting and surgical procedure
Number of subjects: 38
Study 28619305 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study 25735039 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted cataract surgery with capsulotomy and fragmentation
Number of subjects: 67
Study 25735039 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted cataract surgery with only capsulotomy
Number of subjects: 67
Study 25735039 — intervention group
Group type: COMPARATOR
Intervention: Laser-assisted cataract surgery with fragmentation only
Number of subjects: 67
Study 25735039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 67
Study 23971858 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite strategy using a saphenous vein graft as a venous bridge to distribute LIMA flow to the anterolateral territory
Number of subjects: 200
Study 23971858 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy with LIMA-to-LAD anastomosis and revascularization of other anterolateral targets with a separated aorto-coronary saphenous vein graft
Number of subjects: 200
Study 21266215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory care (outpatient treatment)
Number of subjects: 89
Study 21266215 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care (control group)
Number of subjects: 89
Study 19748694 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy (5 x 5 Gy)
Number of subjects: 274
Study 19748694 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 274
Study 19748694 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor leukocyte response on day 1
Number of subjects: 274
Study 19748694 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval of 10 days or more between radiotherapy and surgery
Number of subjects: 274
Study 16715021 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage (ML)
Number of subjects: 14
Study 16715021 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 14
Study 15589715 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 50
Study 15589715 — intervention group
Group type: COMPARATOR
Intervention: Conventional neuroleptic(s)
Number of subjects: 50
Study 11477511 — intervention group
Group type: EXPERIMENTAL
Intervention: Average weight patient
Number of subjects: 122
Study 11477511 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patient
Number of subjects: 122
Study 11477511 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patient
Number of subjects: 122
Study 9405909 — intervention group
Group type: EXPERIMENTAL
Intervention: NPL (neutral protamine lispro)
Number of subjects: 12
Study 9405909 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 12
Study 8423746 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (N = 47)
Number of subjects: 58
Study 8423746 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 11)
Number of subjects: 58
Study 3301001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray, 1.36 mg/attack
Number of subjects: 0
Study 3301001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30914491 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching delivered by a respiratory therapist or nurse
Number of subjects: 215
Study 30914491 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based usual care (control)
Number of subjects: 215
Study 30914491 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 215
Study 29023318 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (GDHT)
Number of subjects: 45
Study 29023318 — intervention group
Group type: COMPARATOR
Intervention: Unspecific hypnotherapy (UHT)
Number of subjects: 45
Study 25600272 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide with 2% nano-hydroxyapatite
Number of subjects: 60
Study 25600272 — intervention group
Group type: COMPARATOR
Intervention: 6% hydrogen peroxide without nano-hydroxyapatite
Number of subjects: 60
Study 25600272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (6% HP with and without n-HA)
Number of subjects: 60
Study 23922054 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab (IV) at doses between 4 and 30 mg/kg
Number of subjects: 0
Study 23922054 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab (IV) co-administered with oral erlotinib
Number of subjects: 0
Study 23922054 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab (IV)
Number of subjects: 0
Study 21327460 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 278
Study 21327460 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth length
Number of subjects: 278
Study 21327460 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 278
Study 19608210 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg GSE per day
Number of subjects: 0
Study 19608210 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg GSE per day
Number of subjects: 0
Study 19608210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18076799 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy using 5‐fluorouracil (5‐FU)
Number of subjects: 167
Study 18076799 — intervention group
Group type: COMPARATOR
Intervention: No perioperative chemotherapy (Control)
Number of subjects: 167
Study 15887535 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback in young persons
Number of subjects: 0
Study 15887535 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback in elderly persons
Number of subjects: 0
Study 12185407 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous citalopram
Number of subjects: 0
Study 12185407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9525792 — intervention group
Group type: EXPERIMENTAL
Intervention: Group family education workshop
Number of subjects: 225
Study 9525792 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual family consultation
Number of subjects: 225
Study 9525792 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 225
Study 7697947 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose zileuton
Number of subjects: 16
Study 7697947 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose zileuton
Number of subjects: 16
Study 7697947 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study 2094221 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg almitrine bismesylate (Vectarion)
Number of subjects: 11
Study 2094221 — intervention group
Group type: COMPARATOR
Intervention: Placebo-pill
Number of subjects: 11
Study 689020 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol-hydrobromide
Number of subjects: 10
Study 689020 — intervention group
Group type: EXPERIMENTAL
Intervention: ritodrin-HCl
Number of subjects: 10
Study 689020 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31244693 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 index
Number of subjects: 285
Study 31244693 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6/n-3 PUFA ratio
Number of subjects: 285